LONDON, UK / ACCESSWIRE / July 2, 2019 / Immutep's AIPAC Phase IIb study of its antigen-presenting cell activator eftilagimod alpha (efti) plus chemotherapy in breast cancer is fully recruited and expected to report top-line data in Q120. The initial tranche of 17 subjects in the first-line lung cancer arm of the TACTI-002 study of efti plus Keytruda (in collaboration with US Merck) has completed enrolment; the cohort will be expanded to 36 subjects if more than four responses are observed (we expect initial response rate data in Q419). Enrolment in second-line lung and head and neck cancer is ongoing. Positive results in AIPAC or TACTI-002 could be a catalyst for a significant deal with a pharma partner. Our valuation is $409m or $12.08 per ADR.
Our valuation is unchanged at $409m, or $12.08 per ADR ($8.79/ADR after diluting for options, warrants and convertible notes). Gross cash at 31 March 2019 was $16.1m. Our forecasts assume the recent initiation of a Phase II study of GSK'781 (IMP731) will have triggered receipt of a $6m milestone payment from GlaxoSmithKline (GSK), which would extend Immutep's cash reach to H220.
Click here to view the full report.
Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Dr. Dennis Hulme, +61 2 8249 8345
Maxim Jacobs, +1 646 653 7027
healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/550604/Edison-Issues-ADR-Update-On-Immutep-IMMP
